Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
McKesson
Colorcon
Dow
Mallinckrodt

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Methylphenidate Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000268 ↗ Cocaine Abuse and Attention Deficit Disorder - 3 Completed New York State Psychiatric Institute N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 ↗ Cocaine Abuse and Attention Deficit Disorder - 3 Completed National Institute on Drug Abuse (NIDA) N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00003266 ↗ Methylphenidate in Treating Patients With Melanoma Completed National Cancer Institute (NCI) Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00003266 ↗ Methylphenidate in Treating Patients With Melanoma Completed Eastern Cooperative Oncology Group Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00012584 ↗ Treatment of Youth With ADHD and Anxiety Completed National Institute of Mental Health (NIMH) N/A 2000-11-01 The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.
NCT00015054 ↗ Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 Completed Cincinnati MDRU Phase 2 1998-09-01 The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Methylphenidate Hydrochloride

Condition Name

Condition Name for Methylphenidate Hydrochloride
Intervention Trials
Attention Deficit Hyperactivity Disorder 99
Attention Deficit Disorder With Hyperactivity 45
ADHD 42
Healthy 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Methylphenidate Hydrochloride
Intervention Trials
Attention Deficit Disorder with Hyperactivity 212
Hyperkinesis 145
Disease 87
Fatigue 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Methylphenidate Hydrochloride

Trials by Country

Trials by Country for Methylphenidate Hydrochloride
Location Trials
United States 622
Canada 41
Israel 26
Germany 21
France 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Methylphenidate Hydrochloride
Location Trials
California 46
Massachusetts 41
New York 41
Texas 40
Ohio 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Methylphenidate Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Methylphenidate Hydrochloride
Clinical Trial Phase Trials
Phase 4 135
Phase 3 79
Phase 2/Phase 3 14
[disabled in preview] 92
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Methylphenidate Hydrochloride
Clinical Trial Phase Trials
Completed 261
Unknown status 45
Recruiting 31
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Methylphenidate Hydrochloride

Sponsor Name

Sponsor Name for Methylphenidate Hydrochloride
Sponsor Trials
National Institute of Mental Health (NIMH) 29
Massachusetts General Hospital 28
National Institute on Drug Abuse (NIDA) 19
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Methylphenidate Hydrochloride
Sponsor Trials
Other 422
Industry 136
NIH 79
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Merck
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.